Ropivacaine is an amide-type local anesthetic used for local or regional anesthesia during surgery and for short-term management of acute pain. Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin.
- Mechanism
- Curator reviewed
Local anesthetics like ropivacaine block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Specifically, they block the sodium channel and decrease chances of depolarization and consequent action potentials. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers.
- Primary indication
- Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.Curator reviewed · 3 structured indications
- Formula / weight
- C17H26N2O · 274.4011 g/mol (avg)
- First approval
- Canada, 2000 · United States, 1996
- Also known as
- (S)-ropivacaine · ropivicaine
- Code names
- TLC590
- Brand names
Resolves to
ZKMNUMMKYBVTFN-HNNXBMFYSA-NSMILESCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Ropivacaine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account